GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharma Advanced Research Co Ltd (NSE:SPARC) » Definitions » 3-Year ROIIC %

Sun Pharma Advanced Research Co (NSE:SPARC) 3-Year ROIIC % : -599.42% (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sun Pharma Advanced Research Co 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Sun Pharma Advanced Research Co's 3-Year ROIIC % for the quarter that ended in Mar. 2024 was -599.42%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Sun Pharma Advanced Research Co's 3-Year ROIIC % or its related term are showing as below:

NSE:SPARC's 3-Year ROIIC % is ranked worse than
97.68% of 991 companies
in the Drug Manufacturers industry
Industry Median: 1.57 vs NSE:SPARC: -599.42

Sun Pharma Advanced Research Co 3-Year ROIIC % Historical Data

The historical data trend for Sun Pharma Advanced Research Co's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Pharma Advanced Research Co 3-Year ROIIC % Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -120.66 69.62 -30.50 80.00 -599.42

Sun Pharma Advanced Research Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -599.42 - - -

Competitive Comparison of Sun Pharma Advanced Research Co's 3-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co's 3-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's 3-Year ROIIC % falls into.


;
;

Sun Pharma Advanced Research Co 3-Year ROIIC % Calculation

Sun Pharma Advanced Research Co's 3-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -4119.156041 (Mar. 2024) - -1459.01 (Mar. 2021) )/( 3418.511 (Mar. 2024) - 2974.722 (Mar. 2021) )
=-2660.146041/443.789
=-599.42%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Sun Pharma Advanced Research Co  (NSE:SPARC) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Sun Pharma Advanced Research Co 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Sun Pharma Advanced Research Co's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sun Pharma Advanced Research Co Business Description

Traded in Other Exchanges
Address
Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in othe4r countries.

Sun Pharma Advanced Research Co Headlines

No Headlines